BeiGene Ltd.
- Country
- 🇨🇳China
- Ownership
- Public
- Established
- 2010-01-01
- Employees
- 10K
- Market Cap
- $22.1B
- Website
- http://www.beigene.com
Study of Sonrotoclax (BGB-11417) Plus Zanubrutinib (BGB-3111) Compared With Venetoclax Plus Obinutuzumab in Participants With Chronic Lymphocytic Leukemia (CLL)
- Conditions
- CLL
- Interventions
- First Posted Date
- 2023-10-10
- Last Posted Date
- 2025-05-16
- Lead Sponsor
- BeiGene
- Target Recruit Count
- 652
- Registration Number
- NCT06073821
- Locations
- 🇺🇸
Alaska Oncology and Hematology, Llc, Anchorage, Alaska, United States
🇺🇸City of Hope National Medical Center, Duarte, California, United States
🇺🇸University of California San Diego (Ucsd) Moores Cancer Center, La Jolla, California, United States
A Study of BGB-A445 in Combination With Other Investigational Agents in Participants With Non-Small Cell Lung Cancer
- Conditions
- Non-Small Cell Lung Cancer
- Interventions
- First Posted Date
- 2023-09-08
- Last Posted Date
- 2025-01-10
- Lead Sponsor
- BeiGene
- Target Recruit Count
- 100
- Registration Number
- NCT06029127
- Locations
- 🇨🇳
Cancer Hospital Chinese Academy of Medical Sciences, Beijing, Beijing, China
🇨🇳Daping Hospital, Third Military Medical University, Chongqing, Chongqing, China
🇨🇳Gansu Provincial Hospital, Lanzhou, Gansu, China
A Study to Evaluate LBL-007 in Combination With Tislelizumab Plus Chemotherapy in Participants With Unresectable Locally Advanced or Metastatic Esophageal Squamous Cell Carcinoma
- Conditions
- Esophageal CancerEsophageal Squamous Cell CarcinomaEsophageal Squamous Cell Carcinoma by AJCC V8 Stage
- Interventions
- First Posted Date
- 2023-08-24
- Last Posted Date
- 2025-01-15
- Lead Sponsor
- BeiGene
- Target Recruit Count
- 118
- Registration Number
- NCT06010303
- Locations
- 🇨🇳
Changhua Christian Hospital, Changhua, Taiwan
🇨🇳Kaohsiung Medical University Chung Ho Memorial Hospital, Kaohsiung, Taiwan
🇨🇳China Medical University Hospital, Taichung, Taiwan
A Study Investigating BGB-26808 Alone or in Combination With Tislelizumab in Participants With Advanced Solid Tumors
- Conditions
- Solid TumorAdvanced Solid Tumor
- Interventions
- First Posted Date
- 2023-08-08
- Last Posted Date
- 2025-05-02
- Lead Sponsor
- BeiGene
- Target Recruit Count
- 107
- Registration Number
- NCT05981703
- Locations
- 🇺🇸
Yale University, Yale Cancer Center, New Haven, Connecticut, United States
🇺🇸Sylvester Cancer Center, University of Miami, Miami, Florida, United States
🇺🇸John Theurer Cancer Center Hackensack University Medical Center, Hackensack, New Jersey, United States
A Study to Investigate Efficacy and Safety of BCL2 Inhibitor Sonrotoclax as Monotherapy and in Combination With Zanubrutinib in Adults With Waldenström Macroglobulinemia
- Conditions
- Waldenstrom's Macroglobulinemia RefractoryWaldenstrom's Macroglobulinemia RecurrentWaldenstrom Macroglobulinemia
- Interventions
- First Posted Date
- 2023-07-19
- Last Posted Date
- 2025-04-13
- Lead Sponsor
- BeiGene
- Target Recruit Count
- 105
- Registration Number
- NCT05952037
- Locations
- 🇺🇸
City of Hope National Medical Center, Duarte, California, United States
🇺🇸Colorado Blood Cancer Institute, Denver, Colorado, United States
🇺🇸Medstar Georgetown University Hospital, Washington, District of Columbia, United States
BGB-A3055 Alone and in Combination With Tislelizumab in Participants With Solid Tumors
- Conditions
- Advanced Solid TumorMetastatic Solid TumorSolid Tumor
- Interventions
- First Posted Date
- 2023-07-07
- Last Posted Date
- 2025-05-21
- Lead Sponsor
- BeiGene
- Target Recruit Count
- 263
- Registration Number
- NCT05935098
- Locations
- 🇺🇸
Advent Health Cancer Institute, Orlando, Florida, United States
🇺🇸University of Iowa Hospitals and Clinics, Iowa City, Iowa, United States
🇺🇸John Theurer Cancer Center Hackensack University Medical Center, Hackensack, New Jersey, United States
Tislelizumab in Combination With Investigational Agents in Participants With Head and Neck Squamous Cell Carcinoma
- Conditions
- Head and Neck Squamous Cell CarcinomaHead and Neck Cancer
- Interventions
- First Posted Date
- 2023-06-18
- Last Posted Date
- 2025-01-08
- Lead Sponsor
- BeiGene
- Target Recruit Count
- 160
- Registration Number
- NCT05909904
- Locations
- 🇹🇭
Siriraj Hospital, Bangkok, Thailand
🇹🇭Ramathibodi Hospital Mahidol University, Bangkok, Thailand
🇰🇷Keimyung University Dongsan Hospital, Dalseogu, Daegu Gwang'yeogsi, Korea, Republic of
A Study of BGB-30813 Alone or in Combination With Tislelizumab in Participants With Advanced or Metastatic Solid Tumors
- First Posted Date
- 2023-06-15
- Last Posted Date
- 2025-04-13
- Lead Sponsor
- BeiGene
- Target Recruit Count
- 200
- Registration Number
- NCT05904496
- Locations
- 🇺🇸
Hackensack University Medical Center, Hackensack, New Jersey, United States
🇺🇸Md Anderson Cancer Center, Houston, Texas, United States
🇺🇸Next Oncology, San Antonio, Texas, United States
A Study to Investigate the Absorption, Metabolism and Excretion of [14C]-BGB-11417
- First Posted Date
- 2023-05-06
- Last Posted Date
- 2025-04-17
- Lead Sponsor
- BeiGene
- Target Recruit Count
- 6
- Registration Number
- NCT05844111
- Locations
- 🇺🇸
Ppd Development, Lp, Austin, Texas, United States
A Study of BGB-21447, a Bcl-2 Inhibitor, in Mature B-Cell Malignancies
- Conditions
- Refractory Chronic Lymphocytic LeukemiaRelapsed Non-Hodgkin LymphomaRefractory Non-Hodgkin LymphomaRelapsed Chronic Lymphocytic LeukemiaRelapsed Follicular LymphomaRelapsed Marginal Zone LymphomaRelapse Diffuse Large B Cell LymphomaRelapsed Small Lymphocytic LymphomaRefractory Follicular LymphomaRefractory Marginal Zone Lymphoma
- Interventions
- First Posted Date
- 2023-04-25
- Last Posted Date
- 2025-05-20
- Lead Sponsor
- BeiGene
- Target Recruit Count
- 112
- Registration Number
- NCT05828589
- Locations
- 🇦🇺
Pindara Private Hospital, Benowa, Queensland, Australia
🇺🇸Mission Cancer and Blood, Waukee, Iowa, United States
🇺🇸Sidney Kimmel Comprehensive Cancer At Johns Hopkins, Baltimore, Maryland, United States